Verily paid Sanofi $122M. ResMed MitiGait. Happify Kopa.

Issue 043.

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week's newsletter had a 62 percent open rate. Here's what's happening this week:

Once again you're looking at a COVID--19-free newsletter. That will be the only mention of it here. There's plenty of other things to read and think about so let's get right onto it...
Regrets, I've had a few: Last week I dashed off a headline for the Livongo year-in-review piece and flubbed the company's year-over-year multiple. Livongo's revenues grew 2.5x between 2018 and 2019, not 1.5x as I wrote in the headline. All of the other information in the article was correct. Apologies for the mistake and thanks to the reader who pointed it out. Eager to hear when I'm wrong, so please don't hesitate to tell me.
Speaking of righted wrongs, BCG's white paper on digital therapeutics that I mentioned last week

Paying Subscribers Only

It's a good one, too.

This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Verily paid Sanofi $122M. ResMed MitiGait. Happify Kopa.

Welcome to E&O.

Paying Subscribers Only

Full access to E&O's research and newsletters.

New! E&O's free weekly newsletter.